Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 4,667 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Signs and Symptoms Clear all
Completed No phase listed Observational Accepts healthy volunteers

Cough Reflex Sensitivity and Bronchial Hyper-responsiveness

NCT01777867
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Chronic Cough, Broncho-hyperreactivity
Interventions
Cough Reflex Sensitivity, Methacholine Challenge
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Oct 15, 2026, 4:45 PM EDT
Active, not recruiting Phase 2 Interventional

Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders

NCT03801434
View directory record Official record
Conditions
BCR-JAK2 Fusion Protein Expression, Blasts 20 Percent or Less of Peripheral Blood White Cells, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, Blasts More Than 5 Percent of Peripheral Blood White Cells, Blasts Under 20 Percent of Bone Marrow Nucleated Cells, Chronic Eosinophilic Leukemia, Not Otherwise Specified, Eosinophilia, Hepatomegaly, Hypereosinophilic Syndrome, JAK2 Gene Mutation, Splenomegaly, TEL-JAK2 Fusion Protein Expression
Interventions
Ruxolitinib
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
4
States / cities
Palo Alto, California • Portland, Oregon • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Phase 2 Interventional Results available

CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

NCT01202409
View directory record Official record
Conditions
Gastrointestinal Cancer
Interventions
Panitumumab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Phase 2 Interventional

Lamivudine for Chronic Hepatitis B

NCT00001457
View directory record Official record
Conditions
Chronic Hepatitis B, Chronic Hepatitis D, Glomerulonephritis, Polyarteritis Nodosa
Interventions
Lamivudine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery

NCT02052557
View directory record Official record
Conditions
Post-operative Pain, Colon Cancer, Diverticulitis
Interventions
Bupivacaine, Bupivacaine liposome suspension
Drug
Lead sponsor
Des Moines University
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Not applicable Interventional

Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer

NCT04540081
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Tobacco Use Cessation, Obesity, Pneumonia, Bacterial, Shingles, Hepatitis C
Interventions
Epic Healthy Planet Population Health Module
Other
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 80 Years
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 15, 2026, 4:45 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A Single Session Community-Based Body Empowerment Session

NCT06139601
View directory record Official record
Conditions
Body Image
Interventions
Virtual single session intervention
Behavioral
Lead sponsor
Equip Health
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Not applicable Interventional Results available

Does Improving Vagal Tone Increase Mitochondrial Bioenergetics

NCT03931330
View directory record Official record
Conditions
Functional Gastrointestinal Disorders, Irritable Bowel Syndrome, Dyspepsia, Functional Abdominal Pain Syndrome
Interventions
Percutaneous neurostimulation
Device
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
12 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Oct 15, 2026, 4:45 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Children s Growth and Behavior Study

NCT02390765
View directory record Official record
Conditions
Obesity, Eating Behaviors, Healthy Volunteers
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
8 Years to 100 Years
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Not applicable Interventional

Hypnosis in Reducing Pain and Other Side Effects in Women Undergoing Surgery for Breast Cancer

NCT00748267
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Nausea and Vomiting, Pain
Interventions
questionnaire administration, hypnotherapy, therapeutic conventional surgery
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 7, 2011 · Synced Oct 15, 2026, 4:45 PM EDT
Completed No phase listed Observational

International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project

NCT05387811
View directory record Official record
Conditions
Liver Cirrhosis, Acute Kidney Injury, Hepatorenal Syndrome
Interventions
Crystalloids, albumin, vasoconstrictors, diuretics, renal replacement therapy
Combination Product
Lead sponsor
Azienda Ospedaliera di Padova
Other
Eligibility
18 Years and older
Enrollment
1,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics and Safety of K-808 (Pemafibrate) in Subjects With Primary Biliary Cholangitis With Compensated Cirrhosis and Without Cirrhosis.

NCT06525311
View directory record Official record
Conditions
Primary Biliary Cholangitis, Compensated Cirrhosis
Interventions
K-808
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Chandler, Arizona • Coronado, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 23, 2025 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Not applicable Interventional

Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects

NCT00926016
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Pioglitazone (Actos)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

No Post Intubation Laryngeal Symptoms

NCT05383417
View directory record Official record
Conditions
Sore-throat, Dysphonia, Dysphagia, Intubation Complication, Anesthesia Intubation Complication, Anesthesia Morbidity, Anesthesia Complication, Anesthesia; Adverse Effect, Anesthesia; Reaction, Throat Disorder, Throat; Wound, Throat Injury
Interventions
EndoClip
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Oct 15, 2026, 4:45 PM EDT
Not listed Phase 1 Interventional

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

NCT03098160
View directory record Official record
Conditions
Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
Interventions
Evofosfamide, Ipilimumab
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Phase 3 Interventional

Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding

NCT00331188
View directory record Official record
Conditions
Esophageal Varices, Portal Hypertension, Gastric Varices, Esophageal Bleeding
Interventions
Sanvar® (vapreotide)
Drug
Lead sponsor
Debiovision
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2008 · Synced Oct 15, 2026, 4:45 PM EDT
Withdrawn Phase 3 Interventional

A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

NCT00891761
View directory record Official record
Conditions
Cancer, Chemotherapy-Induced Nausea and Vomiting, Nausea and Vomiting, Solid Tumor Cancer
Interventions
Dexamethasone, IV casopitant (placebo), IV casopitant (active), Ondansetron
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Tampa, Florida • Robbinsdale, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 15, 2026, 4:45 PM EDT
Active, not recruiting Phase 4 Interventional

Dupilumab for Eosinophilic Esophagitis With Severe Strictures

NCT06352073
View directory record Official record
Conditions
Eosinophilic Esophagitis, EoE
Interventions
Dupilumab
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 15, 2026, 4:45 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Hyperpolarized Noble Gas MR Imaging for Pulmonary Disorders

NCT00846573
View directory record Official record
Conditions
COPD, Cystic Fibrosis, Asthma, Healthy
Interventions
Hyperpolarized Helium-3
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
5 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 15, 2012 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

NCT01952080
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
teduglutide
Drug
Lead sponsor
Shire
Industry
Eligibility
1 Year to 17 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy

NCT03435003
View directory record Official record
Conditions
Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy
Interventions
Aprepitant 80 mg Oral Capsule, scopolamine transdermal, Total intravenous anesthesia, Dexamethasone, Ondansetron, Reglan, Compazine, Sugammadex, Propofol, dexmedetomidine, Fentanyl, Sevoflurane, Desflurane
Drug · Procedure
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Single Dose, 4-Period, 2-Treatment Replicate Design Bioequivalency Study of Granisetron Hydrochloride 1 mg Tablets Under Fasting Conditions

NCT00618254
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
Granisetron
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
19 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 15, 2026, 4:45 PM EDT
Recruiting Not applicable Interventional

Viome Nutritional Programs to Improve Clinical Outcomes for Gastrointestinal Conditions

NCT05465629
View directory record Official record
Conditions
Gastrointestinal Health
Interventions
VIOME Precision Nutrition Program, VIOME-designed condition-based supplements
Combination Product · Dietary Supplement
Lead sponsor
Viome
Industry
Eligibility
25 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Oct 15, 2026, 4:45 PM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis

NCT00956254
View directory record Official record
Conditions
Mucositis, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Fentanyl sublingual spray
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 15, 2026, 4:45 PM EDT